Relative Bioavailability and the Effect of Food on the Bioavailability of LY3023414 in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 10 Nov 2016
At a glance
- Drugs LY 3023414 (Primary)
- Indications Endometrial cancer; Non-small cell lung cancer; Prostate cancer; Solid tumours
- Focus Pharmacokinetics
- Sponsors Eli Lilly
- 03 Nov 2016 Status changed from active, no longer recruiting to completed.
- 06 Oct 2016 Status changed from recruiting to active, no longer recruiting.
- 09 Sep 2016 Planned End Date changed from 1 Sep 2016 to 1 Oct 2016.